Oxford PharmaGenesis showcased a broad range of HealthScience services throughout the ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) meeting, held 7–10 October in Barcelona, Spain. ECTRIMS is the world’s largest annual international conference devoted to basic and clinical research in multiple sclerosis (MS), with this year’s edition attended by more than 9000 clinicians, scientists and industry professionals.
On the eve of the meeting, the Oxford Health Policy Forum launched their MS Brain Health initiative at a standalone symposium attended by more than 200 clinicians and representatives from industry and patient groups. Led by Professor Gavin Giovannoni (Queen Mary University London, Blizard Institute, Barts, London, UK), a distinguished faculty made a concerted ‘call to action’ for improved diagnosis and appropriate treatment for people with MS. In addition to expert presentations on the clinical, scientific and economic issues surrounding MS, George Pepper (Shift.MS) provided insights into the humanistic burden of MS from his own experience of having the condition.
During the ECTRIMS meeting itself, multiple posters from author groups around the world acknowledged the support of Oxford PharmaGenesis in communicating new clinical data in MS. Mobile phone and iPad charging stations throughout the conference hall included interactive touch screen displays that showcased details of ongoing real-world evidence programmes, in an infographics presentation created by Oxford PharmaGenesis.
“It was a privilege to attend ECTRIMS 2015 and see so many important Oxford PharmaGenesis projects come to fruition,” said Dr Richard White, Commercial Director. “In this meeting alone, we have launched an initiative that aims to improve patient care in MS, communicated new clinical data, and demonstrated real-world evidence of the value of treatments for people with MS. Taken together, these initiatives address the needs of patients, physicians, payers and policy-makers, and are a tremendous example of our HealthScience approach in action.”
For more information about the MS Brain Health initiative, see the Twitter page.
